StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued to investors on Saturday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Shares of EGRX stock opened at $4.58 on Friday. The firm has a market capitalization of $59.48 million, a price-to-earnings ratio of 3.88 and a beta of 0.51. Eagle Pharmaceuticals has a one year low of $3.21 and a one year high of $18.31. The company has a 50 day moving average price of $4.93 and a 200 day moving average price of $4.95.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Headlands Technologies LLC grew its position in Eagle Pharmaceuticals by 75.7% during the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock valued at $35,000 after acquiring an additional 2,861 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of Eagle Pharmaceuticals by 623.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,841 shares of the specialty pharmaceutical company’s stock valued at $36,000 after purchasing an additional 5,896 shares in the last quarter. Mackenzie Financial Corp purchased a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter worth about $60,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter worth about $65,000. Finally, Fidelis Capital Partners LLC acquired a new stake in Eagle Pharmaceuticals during the 2nd quarter worth approximately $71,000. 85.36% of the stock is owned by hedge funds and other institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.